Introduction: The Drive Toward Continuous Bioprocessing

The biopharmaceutical industry has undergone a paradigm shift in recent years, moving from traditional batch manufacturing toward integrated, continuous processing. At the heart of this transformation lies continuous chromatography, a technology that enables the seamless purification of therapeutic proteins, monoclonal antibodies, viral vectors, and other complex biologics. As the pipeline of biopharmaceuticals grows more diverse and the demand for cost-effective, high-quality products intensifies, continuous chromatography has emerged as a critical enabler of modern biomanufacturing. This article explores the principles, recent technological advances, practical benefits, and remaining challenges of continuous chromatography, providing a comprehensive overview for professionals seeking to implement or optimize these systems.

Traditional batch chromatography operates in discrete cycles of loading, washing, elution, and regeneration. While well-established, batch processes suffer from inherent inefficiencies: only a fraction of the resin capacity is typically utilized, buffer and resin consumption is high, and the process footprint is large. Continuous chromatography, by contrast, operates in a steady state where feed is constantly applied and product is continuously collected. This approach dramatically improves resin utilization, reduces operating costs, and enhances product consistency. The transition to continuous purification is not merely incremental; it represents a fundamental rethinking of how biopharmaceuticals are produced.

To understand the significance of recent advances, it is essential to first grasp the core principles of continuous chromatography and the varied configurations that have been developed.

Fundamentals of Continuous Chromatography

Principles of Steady-State Operation

In a continuous chromatography system, the separation process occurs without interruption. The stationary phase (resin or membrane) is constantly exposed to a flowing feed stream, while the mobile phase (buffer) is pumped continuously. Components of the mixture interact with the stationary phase according to their binding affinities, resulting in differential migration. The key to continuous operation is the use of multiple columns or a moving bed arrangement that allows one column to be eluted while others are being loaded or regenerated. This overlapping cycle ensures that product is collected at a constant rate, minimizing idle time and maximizing throughput.

The most well-known continuous chromatography configuration is the simulated moving bed (SMB), originally developed for petrochemical and sugar separation. In an SMB system, the columns are connected in a loop, and the inlet and outlet ports are periodically switched to simulate the countercurrent movement of the solid phase. This design achieves high recovery and purity, particularly for binary separations. For biopharmaceuticals, where molecules are larger and more fragile, adaptations such as periodic counter-current (PCC) chromatography and multi-column chromatography (MCSGP) have been developed. PCC systems use three or more columns in a cyclic loading sequence, allowing each column to reach near-saturation before the feed is switched to a fresh column. This maximizes resin utilization and increases productivity by 2-3 times compared to batch processes.

Comparison with Batch Chromatography

In batch chromatography, a fixed volume of feed is loaded onto a single column, and the entire elution is completed before the next batch begins. Resin is used only once through the binding-elution cycle, leading to underutilization because the column cannot be loaded beyond its breakthrough capacity without losing product. Typically, only 30-50% of the resin capacity is exploited in batch mode to avoid yield loss. In contrast, continuous processes push loading well beyond breakthrough, with product breakthrough simply redirecting the flow to an additional column. This results in resin utilization rates of over 90%.

Other critical differences include:

  • Buffer consumption: Continuous systems often require less buffer per gram of product because columns are equilibrated and regenerated in a staggered manner, reducing total volume.
  • Process time: Continuous chromatography enables higher product throughput per unit time due to overlapping steps.
  • Productivity: For Protein A capture of monoclonal antibodies, productivity can increase from ~10 g/L/h in batch to >30 g/L/h in continuous mode.
  • Facility footprint: Continuous systems require smaller columns and less buffer storage, reducing the overall facility size for the same output.

These advantages are driving adoption, especially for high-volume products such as mAbs and biosimilars, but also for labile biologics that benefit from shorter processing times.

Recent Technological Advances

Multicolumn Systems: Beyond SMB and PCC

The most impactful advances in continuous chromatography have centered on multicolumn architectures. While SMB and PCC are well-established, newer systems incorporate more columns (often 4, 6, or even 8) to increase flexibility and accommodate complex separation challenges. For example, the 4-column PCC process developed by GE Healthcare (now Cytiva) allows one column to be regenerated and equilibrated while the other three are sequentially loaded and eluted. This design reduces resin volume by up to 40% compared to batch chromatography and is compatible with existing Protein A resins.

Another important advancement is the Multi-Column Countercurrent Solvent Gradient Purification (MCSGP) process. Originally developed for peptide purification, MCSGP uses a gradient of solvents across columns to separate closely related impurities. This method is particularly useful for the purification of therapeutic peptides, oligonucleotides, and small proteins where batch gradient elution struggles to achieve sufficient purity without sacrificing yield. MCSGP operates by continuously injecting feed while recycling partially purified fractions between columns, effectively concentrating the product band and increasing recovery.

Case in Point: In a study published in the Journal of Chromatography A (2021), researchers demonstrated that a 3-column MCSGP system improved the purification of a synthetic pentapeptide by increasing yield from 60% (batch) to 92% while maintaining >99% purity. Such results underscore the potential of multicolumn gradient processes for high-value therapeutic molecules.

Automation and Real-Time Process Control

Continuous chromatography systems are inherently more complex than batch setups, with multiple pumps, valves, sensors, and columns operating in concert. To manage this complexity, advanced automation and control strategies have been developed. The use of process analytical technology (PAT) is now standard in continuous bioprocessing. Sensors for pH, conductivity, UV absorbance, and near-infrared spectroscopy provide real-time data on column performance. Control algorithms adjust flow rates, switching times, and buffer compositions on the fly to maintain product quality despite variations in feed concentration or column bed height.

Model predictive control (MPC) is increasingly applied to continuous chromatography. In an MPC framework, a first-principles model of the chromatographic process is used to predict future states (e.g., elution profiles) and optimize valve switching times. This reduces the need for empirical tuning and ensures robust operation across a range of feed conditions. Combined with soft sensors that estimate product titer and impurity levels from data already available, automation enables a fully autonomous purification step that adapts to process perturbations.

Leading vendors such as Cytiva, Sartorius, and Repligen have integrated automation platforms specifically designed for continuous chromatography. For example, the ÄKTA process CCS system combines automated column packing, intelligent flow path switching, and built-in PAT for streamlined continuous capture.

Membrane Chromatography Integration

Traditional packed-bed columns used in continuous chromatography can suffer from high pressure drops and mass transfer limitations, particularly as resin particle sizes decrease. Membrane chromatography offers an alternative: a porous membrane with ligands attached to the pore surfaces. Because mass transfer occurs predominantly by convection rather than diffusion, membrane adsorbers operate much faster than packed-bed columns, ideal for continuous processing. Advances in membrane materials (e.g., modified polyethersulfone, regenerated cellulose) and ligand chemistries (e.g., Protein A, ion exchange) have made membrane adsorbers suitable for capture and polishing steps.

In continuous configurations, membrane devices can be arranged in parallel or series to handle high volumetric flow rates. For example, a 3-step continuous purification process for an mAb might use a Protein A membrane adsorber in the first step (capture), an anion exchange membrane in flow-through mode for the second step (viral clearance and removal of host cell proteins), and a cation exchange membrane for the third step (final polishing). The entire process can run continuously with cycle times measured in minutes rather than hours. This approach, sometimes called integrated continuous bioprocessing (ICB), offers a smaller footprint and lower buffer consumption than traditional packed-bed cascades.

A notable example is the Mustang QXT system from Pall Corporation, which uses a disposable membrane adsorber for continuous polishing of monoclonal antibodies. The system is designed for single-use operation, reducing cleaning validation requirements and increasing flexibility for multi-product facilities.

Hybrid and Multimodal Chromatography Approaches

As biopharmaceuticals become more complex (e.g., bispecific antibodies, fusion proteins, gene therapy vectors), standard single-mode chromatography may not provide sufficient selectivity. Hybrid systems combine two or more separation mechanisms—such as ion exchange, hydrophobic interaction, and affinity—in a single continuous process. One promising configuration is continuous electrosorption, where an electric field is applied across a chromatographic column to enhance separation of charged species. Another is simulated moving bed with pH gradients, which enables the separation of variants differing only slightly in isoelectric point.

Multimodal resins, which feature mixed-mode ligands (e.g., cation exchange with hydrophobic phenyl groups), are also being adapted for continuous use. For instance, the Capto MMC resin from Cytiva combines weak cation exchange and hydrophobic interaction, and has been shown in continuous mode to effectively remove high-molecular-weight aggregates and host cell DNA from mAb feed streams. By integrating multiple selectivities, hybrid continuous systems reduce the number of unit operations needed, simplifying the overall purification train.

Benefits of Continuous Chromatography

Increased Throughput and Productivity

The most significant operational benefit of continuous chromatography is a dramatic increase in productivity. Because columns are operated at or beyond breakthrough, the same resin mass can process 2-5 times more feed per unit time compared to batch operation. For a commercial-scale mAb process producing 2 tonnes per year, implementing continuous capture with a Protein A resin can reduce the required resin volume from ~300 L to ~100 L, while maintaining the same resin lifespan. This not only reduces resin cost but also decreases the column size and facility footprint.

Cost Reduction

The economics of continuous chromatography are compelling. According to a 2020 cost-of-goods study by the University College London's bioprocessing group, switching from batch to continuous Protein A capture for an mAb process at 2,000 kg/year scale reduced the total manufacturing cost by 18-20%. The savings came from several sources:

  • Lower resin consumption: The ability to load columns to higher saturation reduces resin purchase and replacement costs.
  • Fewer buffer/buffer storage: Continuous processes use 50-70% less buffer overall, especially for wash and elution steps.
  • Reduced labor: Automation minimizes operator intervention; a single technician can oversee multiple continuous chromatography trains.
  • Smaller facility: Less floor space is needed for columns, skids, and buffer hold tanks, reducing capital expenditure.

These cost advantages are amplified for facilities that adopt fully integrated continuous bioprocessing across upstream and downstream.

Enhanced and Consistent Product Quality

A key advantage of continuous operation is the steady-state environment. Because the process does not start and stop, parameters such as flow rate, temperature, and column pressure remain stable, leading to uniform product quality. This consistency simplifies quality control and regulatory filings. Continuous chromatography also allows for tighter control of impurity clearance. For example, in the capture step, the continuous loading profile ensures that the column is always loaded with a consistent amount of feed per cycle, reducing variability in the elution pool. This reduces the burden on polishing steps and results in higher aggregate removal.

Moreover, because continuous processes are typically shorter (especially when using membrane adsorbers), the product experiences less time in the mobile phase, reducing the risk of degradation or aggregation. This is particularly important for labile molecules such as viral vectors, bispecific antibodies, and fusion proteins.

Scalability and Flexibility

Continuous chromatography scales more linearly than batch. In batch chromatography, scaling up requires larger columns, which can be difficult to pack uniformly with fine resins. In continuous mode, one can scale out by adding more columns of the same size rather than scaling up column diameter. This parallel scaling approach is simpler from an engineering perspective and maintains similar hydrodynamics across scales. For example, a 4-column PCC system at lab scale (0.46 cm diameter columns) can be translated to a production scale (10 cm diameter columns) with minimal changes to the process parameters, as long as the residence time per column is kept constant.

Flexibility is also enhanced by the use of single-use components. Disposable columns, tubing sets, and membrane adsorbers reduce cross-contamination risk and enable rapid changeover between products, making continuous chromatography attractive for contract manufacturing organizations (CMOs) that handle multiple molecules.

Challenges and Barriers to Adoption

Regulatory Hurdles and Validation

Despite the clear benefits, broad adoption of continuous chromatography faces regulatory skepticism. Regulatory agencies, including the FDA and EMA, have traditionally favored batch processes because they are easier to understand, control, and validate. Continuous processes introduce variables not present in batch mode, such as steady-state dynamics, periodic column switching, and real-time control algorithms. To gain regulatory acceptance, manufacturers must demonstrate that their continuous process consistently produces product meeting quality specifications.

The FDA's guidance on quality considerations for continuous manufacturing (published 2021) outlines expectations for system design, process monitoring, and control strategies. Key requirements include:

  • Defining the acceptable range for process parameters (e.g., feed flow rate, column switching frequency) that ensures critical quality attributes are met.
  • Implementing real-time release testing (RTRT) for critical quality attributes (e.g., product titer, purity) using PAT.
  • Demonstrating that start-up and shutdown phases do not affect product quality.
  • Maintaining a thorough cleaning protocol for reusable columns or validating single-use components.

For many companies, the initial cost of regulatory submission (additional characterization studies, extended stability data) can be a barrier, especially for smaller biotechs. However, agencies are increasingly supportive of continuous manufacturing, particularly for high-demand products like mRNA vaccines and gene therapies where speed is critical.

System Complexity and Staff Training

Continuous chromatography systems are more complex than their batch counterparts. They require sophisticated control software, multiple sensors, and careful plumbing to avoid cross-contamination during column switching. Operators must be trained not only in chromatography principles but also in automation, PAT, and troubleshooting of integrated systems. The learning curve can be steep, and many companies prefer to rely on automation vendors for turnkey solutions. The need for specialized expertise can be a barrier, particularly in regions with limited bioprocessing talent.

Resin and Membrane Availability

While many resins designed for batch use perform well in continuous mode (especially for capture), the optimal resin for continuous processes may have different characteristics (e.g., faster binding kinetics, higher capacity at high flow rates). Resin manufacturers are responding by developing continuous-suitable products, but the selection is still narrower than for batch. Similarly, membrane adsorbers for continuous chromatography are less standardized. The lack of widely available, validated continuous-specific consumables can slow adoption.

Feed Variability and Connectivity with Upstream

In a fully integrated continuous process, the downstream train must receive a consistent feed from the upstream bioreactor. For perfusion cultures, the cell culture product stream can vary in titer, composition, and aggregate levels. Continuous chromatography systems must be robust enough to handle these fluctuations without sacrificing yield or purity. Advanced control strategies—such as feed-forward control based on online titer sensors—are essential but add complexity. Companies that are still optimizing their upstream perfusion processes may find it challenging to validate a downstream continuous chromatography step until the upstream is stable.

Future Directions

AI and Machine Learning for Process Optimization

The vast amount of real-time data generated by continuous chromatography systems (sensor readings, elution profiles, column conditions) is ideal for machine learning applications. In the near future, we can expect AI-driven models that predict column breakthrough curves and optimize switching times with minimal experimental data. Reinforcement learning could enable systems to autonomously adapt to disturbances (e.g., feed concentration spikes) while maintaining product quality targets. Early research has shown that neural network models can accurately predict dynamic binding capacities under varying conditions, paving the way for self-optimizing continuous chromatography trains.

Truly Continuous End-to-End Bioprocessing

Continuous chromatography is one piece of a larger puzzle: fully integrated continuous biomanufacturing, where upstream perfusion, downstream capture, polishing, and formulation run in a synchronized, uninterrupted flow. Companies like Sanofi and Lonza have piloted such platforms. In an end-to-end continuous process, the continuous chromatography step must maintain tight synchronization with the bioreactor outflow and the downstream polishing steps. This requires not only robust CCT systems but also buffer preparation and recycling loops, inline conditioning, and real-time release testing. The economic and quality benefits of such integrated processes are expected to be substantial, though technical challenges remain.

Wider Application Beyond Monoclonal Antibodies

While mAbs remain the primary beneficiary, continuous chromatography is increasingly being adapted for other modalities. For gene therapy, continuous purification of adeno-associated viruses (AAVs) using membrane adsorbers and size-exclusion columns in continuous mode is an active area of research. For plasmid DNA (pDNA), continuous ion-exchange chromatography has shown improved yields and lower endotoxin levels. The flexibility of continuous systems—especially the ability to run in capture or polishing mode—makes them applicable to virtually any biological product that requires chromatography.

Single-Use and Disposable Continuous Systems

The trend toward single-use bioprocessing is also shaping continuous chromatography. Vendors are developing fully disposable flow paths, including pre-packed single-use columns, membrane cartridges, and sensor interfaces. These systems minimize cleaning and validation while enabling fast product changeover. For example, Cytiva's ÄKTA process CCS is available in a single-use configuration with gamma-irradiated columns and tubing sets. As the cost of disposables decreases, single-use continuous chromatography is expected to become standard for clinical-scale and even commercial-scale manufacturing.

Conclusion: A Foundational Technology for Modern Biomanufacturing

Advances in continuous chromatography have fundamentally improved the purification of biopharmaceuticals, enabling higher productivity, lower costs, and better product quality. The technology has evolved from niche applications in small-molecule separation to a versatile platform serving a wide range of biologics. Multicolumn systems, real-time process control, membrane integration, and hybrid modalities represent the current frontier, while AI and end-to-end integration point to an even more efficient future.

Challenges around regulatory acceptance, system complexity, and consumable availability remain, but they are being addressed by collaboration between industry, regulators, and technology providers. For any biopharmaceutical manufacturer seeking to increase capacity, reduce costs, or improve process robustness, continuous chromatography is not just an option—it is becoming a strategic imperative. As the technology matures, it will continue to accelerate the development and delivery of life-saving therapies to patients worldwide.